[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Abbasi AN: Clinical features and management of Merkel cell carcinoma. J Pak Med Assoc; 2007 Jul;57(7):368-71
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and management of Merkel cell carcinoma.
  • Merkel cell carcinoma (MCC) is an aggressive dermal tumour of neuroendocrine origin.
  • MCC is a rare tumour and all information pertaining to its behaviour, therapy and prognosis is based on retrospective reports.
  • The two potentially curative treatment modalities are surgery and radiotherapy.
  • It is a rare, highly malignant primary skin tumour, originally called "trabecular carcinoma" of the skin.
  • The optimal therapy is customised and tailored for each individual patient with the appropriate use of operative resection and radiation therapy.
  • Although MCC is classified as a type of neuroendocrine carcinoma, it is less likely to be controlled by systemic chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Merkel Cell / diagnosis. Neuroendocrine Tumors / diagnosis
  • [MeSH-minor] Humans. Prognosis. Radiotherapy, Adjuvant. Survival. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17867262.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 23
  •  go-up   go-down


2. Theunissen P, Fickers M, Goei R: Primary large cell neuroendocrine carcinoma of the presacral region. J Clin Pathol; 2001 Nov;54(11):880-2
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary large cell neuroendocrine carcinoma of the presacral region.
  • The needle biopsy showed a poorly differentiated large cell carcinoma.
  • The patient died of urosepsis after chemotherapy.
  • Histological examination of the presacral tumour showed a large cell carcinoma with a trabecular pattern and strong immunoreactivity for neuroendocrine markers.
  • The tumour was finally classified as a primary large cell neuroendocrine carcinoma of the presacral region.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Pelvic Neoplasms / pathology. Sacrum
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Middle Aged

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11684726.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 4
  • [Other-IDs] NLM/ PMC1731321
  •  go-up   go-down


3. Nies AT, König J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D: Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer; 2001 Nov;94(4):492-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma.
  • Treatment of hepatocellular carcinoma (HCC) by chemotherapy is often impeded by the intrinsic multidrug resistance (MDR) of this frequent primary cancer of the liver.
  • The MDR phenotype can be caused by ATP-dependent export of chemotherapeutic drugs across the plasma membrane being mediated by transporters of the MDR P-glycoprotein family or of the multidrug resistance protein (MRP) family.
  • To elucidate the role of MRP family members in HCC, we analyzed the expression and subcellular localization of MRP1 (ABCC1), MRP2 (ABCC2) and MRP3 (ABCC3); all 3 isoforms have been shown to confer resistance to chemotherapeutic drugs.
  • MRP2 was localized in the plasma membrane in a polarized fashion, either in trabecular structures resembling the canalicular membrane or in the luminal membrane when cells had a pseudoglandular arrangement.
  • MRP3 was localized to the basolateral membrane of carcinoma cells.
  • Double-label immunofluorescence microscopy with antibodies specific for MRP2 or MRP3 indicated that carcinoma cells expressed both MRP isoforms simultaneously.
  • When MRP1 was detected by immunofluorescence microscopy, it was localized on the intracellular membranes of carcinoma cells.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Liver Neoplasms / metabolism. Membrane Transport Proteins. Multidrug Resistance-Associated Proteins / biosynthesis

  • Genetics Home Reference. consumer health - ABCC2 gene.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11745434.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Transport Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / multidrug resistance-associated protein 1; 0 / multidrug resistance-associated protein 2; 0 / multidrug resistance-associated protein 3; 8L70Q75FXE / Adenosine Triphosphate
  •  go-up   go-down


Advertisement
4. Kurth AA, Kim SZ, Bauss F, Müller R, Hovy L: [Anti-osteolytic therapy preserves trabecular structure and mechanical properties of bone in tumor osteolysis]. Z Orthop Ihre Grenzgeb; 2000 Mar-Apr;138(2):146-51
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anti-osteolytic therapy preserves trabecular structure and mechanical properties of bone in tumor osteolysis].
  • [Transliterated title] Eine antiosteolytische Therapie bewahrt die Trabekelstruktur und die mechanischen Eigenschaften des Knochens in Tumorosteolysen.
  • PURPOSE OF THE STUDY: Little is known about the effect of a tumor on the trabecular architecture, therefore we employed an animal model for the assessment of bone quality in tumor osteolysis to determine the alterations of the trabecular architecture in tumor osteolysis and after an interventional treatment with a bisphosphonate.
  • METHODS: To assess the bone mass and the micro-architecture of the trabecular bone in tumor osteolysis we employed a micro-computed tomography system.
  • An interventional treatment of the animals with a bisphosphonate increased the bone mineral content, mechanical and architectural parameters compared to the non-treated, tumor-bearing animals.
  • CONCLUSIONS: These results clearly show a beneficial effect of an anti-osteolytic treatment with a bisphosphonate in regard of bone quality in tumor-induced osteolysis.
  • [MeSH-major] Bone Neoplasms / pathology. Bone and Bones / drug effects. Diphosphonates / pharmacology. Osteolysis / pathology
  • [MeSH-minor] Animals. Bone Density / drug effects. Bone Resorption / pathology. Carcinoma 256, Walker / pathology. Disease Models, Animal. Humans. Neoplasm Transplantation. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10820881.001).
  • [ISSN] 0044-3220
  • [Journal-full-title] Zeitschrift für Orthopädie und ihre Grenzgebiete
  • [ISO-abbreviation] Z Orthop Ihre Grenzgeb
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Diphosphonates; 114084-78-5 / ibandronic acid
  •  go-up   go-down


5. Alvarez E, Westmore M, Galvin RJ, Clapp CL, Considine EL, Smith SJ, Keyes K, Iversen PW, Delafuente DM, Sulaimon S, Zambrano C, Ma L, Sato M, Martin TJ, Teicher BA, Galbreath EJ: Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption. Clin Cancer Res; 2003 Nov 15;9(15):5705-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption.
  • The current study describes an in vivo model of 13762 rat mammary carcinoma tumor cell-induced osteolysis in which PTHrP and TGF-beta1 expression is observed.
  • Tumor cells were implanted into the intramedullary space of the proximal tibia of rats, and the time course of tumor progression was evaluated using radiographic and microcomputed tomography scanning techniques.
  • Trabecular bone mineral density, cortical bone mineral density, and whole bone mineral density were measured (in mg/cm(3)).
  • Trabecular bone mineral density and whole bone mineral density were significantly decreased by 21 days after implantation (48% and 26%, respectively).
  • The results of this study demonstrate the ability of 13762 rat mammary carcinoma cells to elicit a measurable osteolysis and that bisphosphonates inhibit the tumor-induced bone resorption in this model.
  • [MeSH-major] Bone Resorption / prevention & control. Diphosphonates / therapeutic use. Mammary Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / toxicity. Cell Division / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Disease Progression. Female. Humans. Neoplasm Metastasis. Osteolysis / etiology. Osteolysis / prevention & control. Parathyroid Hormone-Related Protein / analysis. Parathyroid Hormone-Related Protein / genetics. Rats. Rats, Inbred F344. Transforming Growth Factor beta / analysis. Transforming Growth Factor beta / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2003 Nov 15;9(15):5433-4 [14654520.001]
  • (PMID = 14654555.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; 0 / Parathyroid Hormone-Related Protein; 0 / Transforming Growth Factor beta
  •  go-up   go-down


6. Arrington SA, Fisher ER, Willick GE, Mann KA, Allen MJ: Anabolic and antiresorptive drugs improve trabecular microarchitecture and reduce fracture risk following radiation therapy. Calcif Tissue Int; 2010 Sep;87(3):263-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anabolic and antiresorptive drugs improve trabecular microarchitecture and reduce fracture risk following radiation therapy.
  • Many patients with symptomatic bone metastases receive radiation therapy, even though radiation is known to have potential adverse effects on bone.
  • We hypothesized that the concurrent use of a bisphosphonate drug (zoledronic acid, ZA) or a combination of ZA plus an anabolic agent (parathyroid hormone, PTH) would lead to improvements in the microarchitecture and mechanical properties of irradiated bone.
  • Human breast cancer cells were injected into the distal femur of 56 female nude mice, which were then divided into four groups: no treatment (0 Gy), radiation administered 4 weeks postinjection (20 Gy), radiation plus ZA (12.5 microg/kg weekly from weeks 4 to 12) (20 Gy + ZA), and radiation followed by ZA (25 microg/kg weekly from weeks 4 to 8) and PTH(1-34) (100 microg microg/kg daily from weeks 8 to 12) (20 Gy + ZA + PTH).
  • At the end of the study, micro-computed tomography and mechanical testing were used to quantify bone microarchitecture and bone strength.
  • Radiation alone failed to prevent tumor-induced decreases in bone mineral density (BMD), trabecular bone volume, and bone strength.
  • Treatment with 20 Gy + ZA or 20 Gy + ZA + PTH as adjuncts to radiation was effective at preserving trabecular bone architecture and bone strength at normal levels.
  • Supplemental use of PTH did not result in further increases in bone strength but was associated with significant increases in BMD and bone mass, suggesting that it may be beneficial in enhancing bone architecture following radiation therapy.
  • [MeSH-major] Anabolic Agents / administration & dosage. Bone Density Conservation Agents / administration & dosage. Carcinoma / radiotherapy. Diphosphonates / administration & dosage. Femoral Neoplasms / radiotherapy. Imidazoles / administration & dosage. Osteolysis / prevention & control. Parathyroid Hormone / administration & dosage
  • [MeSH-minor] Animals. Bone Density / drug effects. Bone and Bones. Drug Therapy, Combination. Female. Mice. Mice, Nude

  • MedlinePlus Health Information. consumer health - Anabolic Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20563797.001).
  • [ISSN] 1432-0827
  • [Journal-full-title] Calcified tissue international
  • [ISO-abbreviation] Calcif. Tissue Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anabolic Agents; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 0 / Parathyroid Hormone; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


7. Xiao EH, Li JQ, Huang JF: Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization. World J Gastroenterol; 2004 Jan 15;10(2):190-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization.
  • AIM: To evaluate the effects of p53 on apoptosis and proliferation of hepatocellular carcinoma (HCC) cells treated with transcatheter arterial chemoembolization (TACE).
  • TACE group included 79 patients who had 1-5 courses of TACE before surgery, of them, 11 patients had 1-4 courses of chemotherapy (group A), 33 patients had 1-5 courses of chemotherapy combined with iodized oil (group B), 23 patients had 1-3 courses of chemotherapy, iodized oil and gelatin sponge (group C), 12 patients had 1-3 courses of chemotherapy combined with iodized oil, ethanol and gelatin sponge (group D).
  • RESULTS: P53 protein expressions in trabecular and clear cells in HCC specimens were significantly lower than that in pseudoglandular, solid, poorly differentiated or undifferentiated and sclerosis HCC (P<0.05).
  • [MeSH-major] Apoptosis / physiology. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14716820.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein
  • [Other-IDs] NLM/ PMC4717001
  •  go-up   go-down


8. Banfi A, Podestà M, Fazzuoli L, Sertoli MR, Venturini M, Santini G, Cancedda R, Quarto R: High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia. Cancer; 2001 Nov 1;92(9):2419-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia.
  • BACKGROUND: Osteoporosis is a sequela of hemopoietic cell transplantation with a complex multifactorial pathogenesis in which the relative role of chemotherapy and irradiation is not completely understood.
  • Therefore, the authors investigated the toxicity of chemotherapy-only conditioning regimens on bone homeostasis and bone marrow osteoprogenitors, its dose dependency, and the mechanism of chemotherapy-induced osteopenia.
  • METHODS: Fifty-one patients with high-grade non-Hodgkin lymphoma or breast carcinoma who had been treated previously with high-dose + peripheral blood progenitor cell or conventional chemotherapy or who had not received any treatment (prechemotherapy) were enrolled.
  • RESULTS: Both high-dose chemotherapy regimens caused a 50% reduction in CFU-f frequency, independently of gonadal function status, whereas conventional chemotherapy and prechemotherapy groups were unaffected.
  • Bone mineral density was measured in 26 non-Hodgkin lymphoma patients and again only high-dose chemotherapy caused a 10% loss in cortical bone and 20% in trabecular bone.
  • No endocrine abnormality was found except for the secondary amenorrhea uniformly induced in the high-dose chemotherapy group.
  • CONCLUSIONS: Chemotherapy without irradiation shows a dose-dependent toxicity to bone marrow stromal osteoprogenitors and can cause osteopenia by direct damage of the osteoblastic compartment, as a mechanism distinct from and summable to hypogonadism.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Diseases, Metabolic / chemically induced. Bone Marrow Transplantation. Breast Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Transplantation Conditioning / adverse effects
  • [MeSH-minor] Adult. Amenorrhea / chemically induced. Bone Density. Bone Marrow Cells / drug effects. Dose-Response Relationship, Drug. Female. Hematopoietic Stem Cells. Homeostasis. Humans. Male. Middle Aged. Osteoporosis / chemically induced. Osteoporosis / physiopathology


9. Swann MH, Yoon J: Merkel cell carcinoma. Semin Oncol; 2007 Feb;34(1):51-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma.
  • Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous cancer that predominately affects elderly Caucasians with fair skin and has a propensity for local recurrence and regional lymph node metastases.
  • A variety of terms have been used to describe this tumor, including trabecular cell carcinoma, neuroendocrine or primary small cell carcinoma of the skin, and anaplastic cancer of the skin.
  • Patients with MCC frequently present with a nonspecific erythematous or violaceous firm nodule or small plaque that may be surrounded by small satellite tumors.
  • It may be difficult to accurately diagnose MCC by light microscopy alone and ancillary techniques, including electron microscopy and immunohistochemistry, may be necessary to make a definitive diagnosis.
  • Nonetheless, for localized disease most guidelines include wide local excision of the primary tumor either alone or with radiation therapy.
  • Systemic chemotherapy, akin to regimens for small cell carcinoma of the lung, may be considered as an adjuvant following surgery or to treat locoregional or distant disease.
  • Such patients have a grim prognosis with a median survival of 9 months.
  • Successful outcomes are most often seen in patients with early diagnosis and complete excision.
  • [MeSH-major] Carcinoma, Merkel Cell. Skin Neoplasms
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Lymphatic Metastasis. Neoplasm Recurrence, Local / diagnosis. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270666.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


10. Weisser H, Hartschuh W, Greiner A, Bischof M, Enk A, Helmbold P: [Merkel cell carcinoma--clinically often misjudged]. Dtsch Med Wochenschr; 2007 Jul 30;132(30):1581-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell carcinoma--clinically often misjudged].
  • Merkel cell carcinoma is a rare, rapidly growing, highly malignant dermal tumor which occurs preferentially on light-exposed skin in advanced age.
  • The five-year overall survival rate is only about 65 %, despite rigorous therapy.
  • The histological pattern is characterized by trabecular strands of small, uniform cells with large basophilic nuclei and typical neuroendocrine granules.
  • The diagnosis is confirmed immunohistochemically by neuroendocrine and epithelial markers.
  • The excision of the primary tumor is regarded as first-line therapy.
  • Adjuvant chemotherapy can be applied in this stage, as in small-cell bronchial carcinoma.
  • Despite good response to radiatiotherapy and chemotherapy, with at least prolonged recurrence-free intervals, Merkel cell carcinoma is rarely curable at the distant metastasizing stage.
  • Individually defined, aggressive treatment,including radiatiotherapy, may in future considerably improve the prognosis, especially in the early stages of the disease.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17628844.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


11. Kushwaha AC, Whitman GJ, Stelling CB, Cristofanilli M, Buzdar AU: Primary inflammatory carcinoma of the breast: retrospective review of mammographic findings. AJR Am J Roentgenol; 2000 Feb;174(2):535-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary inflammatory carcinoma of the breast: retrospective review of mammographic findings.
  • OBJECTIVE: Our goal was to describe the mammographic characteristics of primary inflammatory carcinoma of the breast.
  • MATERIALS AND METHODS: We identified the medical records of 43 women who participated in a chemotherapy protocol for primary inflammatory carcinoma of the breast between 1994 and 1997.
  • Two radiologists independently reviewed the 26 mammograms obtained before patients underwent treatment.
  • RESULTS: Mammographic findings included skin thickening in 24 patients (92%), diffusely increased density in 21 patients (81%), trabecular thickening in 16 patients (62%), axillary lymphadenopathy in 15 patients (58%), architectural distortion or focal asymmetric density in 13 patients (50%), and nipple retraction in 10 patients (38%).
  • CONCLUSION: Diffuse mammographic abnormalities such as skin thickening, increased density, trabecular thickening, and axillary lymphadenopathy are common at presentation in patients with primary inflammatory carcinoma of the breast.
  • [MeSH-major] Adenocarcinoma / radiography. Breast Neoplasms / radiography. Mammography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10658737.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


12. Kafé H, Verbavatz JM, Cochand-Priollet B, Castagnet P, Vieillefond A: Collecting duct carcinoma: an entity to be redefined? Virchows Arch; 2004 Dec;445(6):637-40
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collecting duct carcinoma: an entity to be redefined?
  • Collecting duct carcinomas (CDCs) are highly aggressive tumors with poor survival at 1 year and are often metastatic at the time of diagnosis.
  • It has been shown that patients may have better survival when treated with a chemotherapy regimen used for urothelial carcinoma.
  • Such tumors must therefore be recognized, but their pathological diagnosis remains difficult.
  • The two main differential diagnoses are renal pelvis urothelial carcinoma with infiltration of the kidney and/or high-grade and high-stage papillary renal cell carcinoma.
  • The aim of our study was to compare the immunophenotype of 14 CDCs with 6 renal pelvis urothelial carcinomas (RPUC) infiltrating the medulla.
  • It coincided with an urothelial-like trabecular and tubular pattern.
  • (1) the trabecular and tubular variant of CDC with the urothelial AQP-3+, vimentin- phenotype can be included in the spectrum of urothelial diseases;.
  • [MeSH-major] Kidney Neoplasms / pathology. Kidney Tubules, Collecting

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Renal Physiol. 2000 Jan;278(1):F13-28 [10644652.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] Science. 1992 Apr 17;256(5055):385-7 [1373524.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):111-6 [11815966.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1138-40 [14501710.001]
  • [Cites] J Biol Chem. 1998 Apr 3;273(14):8407-12 [9525951.001]
  • [Cites] Am J Physiol. 1995 Nov;269(5 Pt 2):F663-72 [7503232.001]
  • [Cites] Histopathology. 1985 Oct;9(10):1037-50 [2417930.001]
  • [Cites] Histopathology. 1991 Feb;18(2):115-22 [1707029.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):54-67 [9503506.001]
  • [Cites] Hum Pathol. 1990 Apr;21(4):449-56 [2318486.001]
  • (PMID = 15480763.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AQP3 protein, human; 0 / Aquaporins; 0 / Vimentin; 158801-98-0 / Aquaporin 3
  •  go-up   go-down


13. Liu LN, Chen GY, Wang P, Zhang CH, Huang SF: [Papillary renal cell carcinoma: clinico-pathologic studies of 33 cases]. Zhonghua Zhong Liu Za Zhi; 2005 Feb;27(2):102-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Papillary renal cell carcinoma: clinico-pathologic studies of 33 cases].
  • OBJECTIVE: To investigate the morphologic features, differential diagnosis, prognosis and histogenesis of papillary renal cell carcinoma (PRCC).
  • Light microscopic observation, immunohistochemical assay of EMA, CK7, CD10, Vim, 34 beta E12 by tissue chip were performed.
  • Besides typical papillae, inconspicuous papillary patterns, such as trabecular, tubular, micronodular and pseudostratified patterns could be seen.
  • Tumors were of two major types: basophilic type (n = 10), with small cuboid cell and pale cytoplasm (n = 10), 9 of them were low in Fuhrman grading; eosinophilic type (n = 22) with large columnar cells, rich in eosinophilic cytoplasm, 19 of them were high in Fuhrman grading.
  • The remaining case was of clear cell type.
  • The basophilic tumors were all positive for distal tubule marker EMA/CK7, none for proximal tubule marker CD10, 7 tumors positive for Vim.
  • The prognosis of PRCC was worse than that of chromophobe renal cell carcinoma.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Keratin-7. Keratins / metabolism. Kidney Tubules / metabolism. Male. Middle Aged. Mucin-1 / metabolism. Neprilysin / metabolism. Survival Rate. Vimentin / metabolism

  • Genetic Alliance. consumer health - Papillary renal cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946550.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Mucin-1; 0 / Vimentin; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


14. Fukunaga M, Fujiwara Y, Naito Z: Hepatoid carcinoma with serous component of the fallopian tube: a case report with immunohistochemical and ultrastructural studies. Int J Gynecol Pathol; 2006 Jul;25(3):233-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid carcinoma with serous component of the fallopian tube: a case report with immunohistochemical and ultrastructural studies.
  • A very rare case of hepatoid carcinoma with serous component arising in the fallopian tube of a 79-year-old woman is presented.
  • The tumor was composed of hepatoid carcinoma (90%) and serous carcinoma (10%) components.
  • The hepatoid carcinoma was histologically characterized by a proliferation of round to polygonal cells arranged in a trabecular, tubular, sinusoidal, papillary, or solid pattern.
  • Immunohistochemically, the hepatoid carcinoma was positive for alpha-fetoprotein, polyclonal carcinoembryonic antigen (CEA), hepatocyte paraffin 1, albumin, epithelial membrane antigen, and cytokeratin (CAM5.2).
  • Ultrastructurally, the cytoplasm contained abundant ribosomes, moderate amounts of mitochondria, and rough endoplasmic reticulum that developed into a meshwork and contained mitochondria within it.
  • The association with serous carcinoma indicates mullerian origin rather than germ cell origin.
  • The patient received chemotherapy and was alive without disease at 10 months after surgery.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Fallopian Tube Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratins / analysis. Microscopy, Electron, Transmission. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810059.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 68238-35-7 / Keratins
  •  go-up   go-down


15. Conner MG, Richter H, Moran CA, Hameed A, Albores-Saavedra J: Small cell carcinoma of the cervix: a clinicopathologic and immunohistochemical study of 23 cases. Ann Diagn Pathol; 2002 Dec;6(6):345-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the cervix: a clinicopathologic and immunohistochemical study of 23 cases.
  • Twenty-three patients with primary small cell carcinoma of the uterine cervix are presented.
  • Histologically, the tumors were densely cellular and showed trabecular nesting or a sheet-like pattern.
  • There was a minor component of large cell neuroendocrine carcinoma in three cases, while foci of adenocarcinoma were identified in two cases.
  • Ten small cell carcinomas were immunoreactive for chromogranin, 13 for synaptophysin, and 10 expressed p53 protein.
  • Treatment modalities included hysterectomy alone or combined with chemotherapy and/or radiation therapy.
  • A few patients received chemotherapy and/or radiation alone.
  • Small cell carcinoma of the cervix is a highly aggressive neoplasm.
  • However, early diagnosis and combined therapeutic modalities may lead to longer survival in some patients.
  • Although the use of immunohistochemistry may be helpful in the diagnosis, small cell carcinoma still remains a morphologic diagnosis.
  • [MeSH-major] Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Biomarkers. Chromogranins / metabolism. Female. Follow-Up Studies. Humans. Immunohistochemistry. Keratins / metabolism. Middle Aged. Synaptophysin / metabolism. Treatment Outcome. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12478483.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / Chromogranins; 0 / Synaptophysin; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins
  •  go-up   go-down


16. Ruangpratheep C, Lohachittranond C, Poonpracha T, Punyarit P: OCT4 expression on a case of poorly differentiated (insular) carcinoma of the thyroid gland and minireview. J Med Assoc Thai; 2005 Nov;88 Suppl 3:S281-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] OCT4 expression on a case of poorly differentiated (insular) carcinoma of the thyroid gland and minireview.
  • Poorly differentiated (insular) carcinoma of the thyroid gland is rare and defined as follicular-cell neoplasms that show limited evidence of structural follicular cell differentiation and occupy both morphologically and behaviourally an intermediate position between differentiated (follicular and papillary carcinomas) and undifferentiated (anaplastic) carcinomas.
  • The authors report a case of a 37-year-old Thai woman who presented with a prolonged left thyroid nodule.
  • Final pathological diagnoses of her mass were poorly differentiated (insular) carcinoma with lymphovascular invasion and nodular goiter.
  • The tumor cell arrangements were nest (insular) and trabecular patterns with some follicular formations.
  • The authors believe that poorly differentiated (insular) carcinoma of the thyroid gland probably develops from the remnant of thyroid stem cells and is not associated with dedifferentiation (anaplasia or loss of cellular differentiation) from nodular goiter or cells of other thyroid carcinomas.
  • However, there is only one case of immunohistochemistry of OCT4 in poorly differentiated (insular) carcinoma of the thyroid gland.
  • Further research on expression of OCT4 gene on thyroid cancers and other malignant tumors relating to tumorigenic cancer cells (cancer stem cells) may be useful to prognostic evaluation and administration of a new chemotherapy and/or radiotherapy that is specific for tumor-initiating cells.
  • [MeSH-major] Carcinoma / metabolism. Octamer Transcription Factor-3 / metabolism. Thyroid Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858970.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Octamer Transcription Factor-3
  • [Number-of-references] 14
  •  go-up   go-down


17. Rhemtula H, Grayson W, van Iddekinge B, Tiltman A: Large-cell neuroendocrine carcinoma of the uterine cervix--a clinicopathological study of five cases. S Afr Med J; 2001 Jun;91(6):525-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-cell neuroendocrine carcinoma of the uterine cervix--a clinicopathological study of five cases.
  • OBJECTIVE: The present study describes 5 cases of large-cell neuroendocrine carcinoma (LCNEC) of the uterine cervix, evaluating their clinical features and pathological profiles.
  • A histopathological diagnosis was obtained after biopsy material from all 5 patients was examined microscopically and subjected to immunohistochemical staining with MNF116 (pankeratin) synaptophysin and chromagranin A, all of which are neuroendocrine markers.
  • None of the 5 patients in this series received chemotherapy or underwent surgery.
  • Three of the 5 patients presented with advanced-stage cervical carcinoma, with evidence of metastases in 2 of them.
  • Treatment responses and long-term survival in our series proved to be disappointing as 3 of the 5 patients died in less than 6 months.
  • On histopathological examination, all 5 tumours showed features of a high-grade poorly differentiated malignant neoplasm with ulceration and extensive tumour necrosis including trabecular and organoid growth patterns.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Parity. Prognosis. Survival Analysis. Synaptophysin. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11455720.001).
  • [ISSN] 0256-9574
  • [Journal-full-title] South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • [ISO-abbreviation] S. Afr. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Synaptophysin
  •  go-up   go-down


18. Ejaz A, Wenig BM: Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis. Adv Anat Pathol; 2005 May;12(3):134-43
Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis.
  • Sinonasal undifferentiated carcinoma (SNUC) is an uncommon, highly aggressive, and clinicopathologically distinctive carcinoma of uncertain histogenesis.
  • The light microscopic features include the presence of a hypercellular proliferation with varied growth patterns, including trabecular, sheet-like, ribbon, lobular, and organoid patterns.
  • Adjunct analyses (eg, immunohistochemistry, electron microscopy, and molecular biologic studies) are often required in the diagnosis of SNUC and in differentiating it from other undifferentiated malignant neoplasms.
  • The treatment of SNUC includes aggressive multimodality therapy, including surgical resection and adjuvant therapy (ie, radiotherapy, chemotherapy).
  • The prognosis associated with SNUC is poor, and death due to disease often occurs within short periods following the diagnosis.
  • Irrespective of its cell of origin and perhaps even in the face of differentiated foci in limited parts of the tumor, given its rather unique clinicopathologic characteristics, this tumor should be identified and classified as SNUC, thereby differentiating it from the other specific types of sinonasal carcinomas and nonepithelial malignant tumors.
  • [MeSH-major] Carcinoma / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma, Neuroendocrine / pathology. Diagnosis, Differential. Esthesioneuroblastoma, Olfactory / pathology. Humans. Lymphoma, T-Cell, Cutaneous / pathology. Male. Melanoma / pathology. Middle Aged. Nasal Cavity / pathology. Nose Neoplasms / pathology. Prognosis. Rhabdomyosarcoma / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900114.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


19. Ghofrani M, Sosa JA, Ocal IT, Angeletti C: Fine needle aspiration of poorly differentiated oxyphilic (Hürthle cell) thyroid carcinoma: a case report. Acta Cytol; 2006 Sep-Oct;50(5):560-2
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration of poorly differentiated oxyphilic (Hürthle cell) thyroid carcinoma: a case report.
  • BACKGROUND: Poorly differentiated oxyphilic (Hürthle cell) carcinomas are a more recently described variant of poorly differentiated thyroid carcinoma and are characterized by a prominent Hürthle cell component in a solid or trabecular arrangement.
  • Clinically, poorly differentiated oxyphilic carcinomas behave more aggressively as compared to classic Hürthle cell carcinomas, which have a predominantly follicular pattern.
  • CASE: A 73-year-old man with a long history of radioactive iodine and levothyroxine therapy for multinodular goiter presented with a painful, rapidly expanding, 6-cm, left thyroid mass with aggressive radiologic features.
  • Fine needle aspiration biopsy of the mass yielded extremely cellular smears with a dual population of medium-sized follicular cells and numerous Hürthle cells.
  • Subsequent thyroidectomy confirmed the malignant nature of this Hürthle cell-rich tumor, warranting a diagnosis of poorly differentiated oxyphilic (Hürthle cell) thyroid carcinoma.
  • CONCLUSION: Poorly differentiated oxyphilic thyroid carcinoma is an aggressive variant of Hürthle cell carcinomas and must enter the differential diagnosis when fine needle aspiration biopsy of a radiologically aggressive thyroid mass yields extremely hypercellular smears with a prominent Hürthle cell component.
  • [MeSH-major] Adenocarcinoma / diagnosis. Epithelial Cells / pathology. Lung Neoplasms / diagnosis. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Disease Progression. Goiter, Nodular / complications. Goiter, Nodular / drug therapy. Goiter, Nodular / radiotherapy. Humans. Iodine Radioisotopes / therapeutic use. Male. Neoplasm Invasiveness. Thyroidectomy. Thyroxine / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17017447.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


20. Lamoureux F, Ory B, Battaglia S, Pilet P, Heymann MF, Gouin F, Duteille F, Heymann D, Redini F: Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid. Int J Cancer; 2008 Feb 15;122(4):751-60
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.
  • Animal models that mimic osteoblastic metastases associated with prostate carcinoma are required to improve the therapeutic options in humans.
  • A new model was then developed and characterized in immunocompetent rats.
  • The bisphosphonate zoledronic acid (ZOL) was tested to validate this model as a therapeutic application.
  • A disorganization of the trabecular bone at the growth zone level was observed in vivo after intraosseous AT6-1 cell injection as well as cortical erosion.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone Neoplasms / drug therapy. Diphosphonates / therapeutic use. Disease Models, Animal. Imidazoles / therapeutic use. Osteosarcoma / drug therapy. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Bone Marrow Cells / drug effects. Bone Remodeling / drug effects. Cell Cycle / drug effects. Cell Proliferation / drug effects. Humans. Male. Mice. Mice, Inbred C3H. Osteoblasts / drug effects. Osteoblasts / metabolism. Osteogenesis / drug effects. Rats. Rats, Sprague-Dawley. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17960623.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


21. Russmann S, Zimmermann A, Krähenbühl S, Kern B, Reichen J: Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol; 2001 Mar;13(3):287-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis.
  • After diagnosis of veno-occlusive disease (VOD) and hepatocellular carcinoma (HCC) via biopsy, tumour resection was performed.
  • The histology was typical for a well-differentiated HCC with trabecular and pseudoglandular structures.
  • Neighbouring liver tissue was atrophic, with nodular regenerative hyperplasia (NRH), peliosis-like sinusoidal ectasias and intra-sinusoidal accumulation of blood, associated with peri-sinusoidal fibrosis.
  • Although none of the well-established risk factors for HCC such as cirrhosis, hepatitis B/C, metabolic liver disease or toxins were present, this patient developed HCC.
  • [MeSH-major] Azathioprine / adverse effects. Carcinoma, Hepatocellular / chemically induced. Hepatic Veno-Occlusive Disease / chemically induced. Immunosuppressive Agents / adverse effects. Liver Neoplasms / chemically induced
  • [MeSH-minor] Aged. Colitis, Ulcerative / drug therapy. Humans. Hyperplasia. Male


22. Acebo E, Vidaurrazaga N, Varas C, Burgos-Bretones JJ, Díaz-Pérez JL: Merkel cell carcinoma: a clinicopathological study of 11 cases. J Eur Acad Dermatol Venereol; 2005 Sep;19(5):546-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma: a clinicopathological study of 11 cases.
  • OBJECTIVE: To report our 12-year experience with Merkel cell carcinomas (MCCs) from a clinical and pathological point of view.
  • Age, gender, location, size, stage, treatment and follow-up data were collected.
  • RESULTS: Six females and five males with a mean age of 82 years were identified.
  • At diagnosis, one patient was in stage Ia, six in stage Ib, three in stage II and one in stage III.
  • Additional treatment consisted of lymph node dissection in two patients, radiotherapy in four patients and systemic chemotherapy in one patient.
  • Local recurrence developed in five patients.
  • Additional small-size cell pattern and trabecular pattern were observed in seven and six cases, respectively.
  • Wide surgical excision is the recommended treatment.
  • Lymph node dissection, adjuvant radiotherapy and chemotherapy decrease regional recurrences but have not been demonstrated to increase survival.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / therapy. Neoplasm Invasiveness / pathology. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Spain. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164706.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


23. Tałalaj M, Kapitan-Malinowska B, Debski K, Nowakowski R, Marcinowska-Suchowierska E, Witeska A: [Administration of 1 alpha-OH vitamin D3 and calcium prevents bone mass loss in patients with advanced prostatic carcinoma after orchidectomy treated with complete androgenic blockade]. Endokrynol Pol; 2005 May-Jun;56(3):225-32
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Administration of 1 alpha-OH vitamin D3 and calcium prevents bone mass loss in patients with advanced prostatic carcinoma after orchidectomy treated with complete androgenic blockade].
  • Complete androgenic blockade used in the treatment of advanced prostatic carcinoma can be attained by administration of antiandrogens in orchidectomized patients or by combined therapy with LH-RH analogs and antiandrogens.
  • The treatment, however, decreases the influence of both androgens end estrogens on bone tissue and may result in bone mass loss and increased propensity to fractures.
  • The purpose of the study was to determine the influence of complete androgenic blockade on bone mass and skeletal metabolism in men with advanced prostatic carcinoma and to assess whether 1alpha-OH vitamin D3 (1alpha-OHD3) together with calcium supplementation is able to prevent bone mass loss in men treated with complete androgenic blockade.
  • 51 patients with advanced prostatic carcinoma, with skeletal metastases, aged 44 - 86, mean 68 ys were included into a 12-month prospective study.
  • All patients were treated with orchidectomy followed by therapy with flutamide in a dose of 750 mg daily.
  • It was found that the 12-month treatment with complete androgenic blockade resulted in a decrease in bone mineral density (BMD) by 8.1% in the lumbar spine, by 6.3% in the femoral neck and by 3.5% in the total skeleton.
  • Therapy with 1alpha-OHD3 and CaCO3 caused complete inhibition of bone tissue loss in the lumbar spine and resulted in an increase in BMD by 2.2% in femoral neck and by 1.9% in the total skeleton.
  • CONCLUSIONS: in patients with advanced prostatic carcinoma treated with complete androgenic blockade acceleration of bone mass loss is observed; treatment with 1alpha-OHD3 and CaCO3 is able to prevent both trabecular and compact bone loss.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Bone Density Conservation Agents / administration & dosage. Calcium, Dietary / administration & dosage. Hydroxycholecalciferols / administration & dosage. Orchiectomy / adverse effects. Osteomalacia / prevention & control. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Androgen Antagonists / administration & dosage. Androgen Antagonists / adverse effects. Bone Density / drug effects. Bone Regeneration / drug effects. Calcium / blood. Drug Therapy, Combination. Flutamide / administration & dosage. Flutamide / adverse effects. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Calcium.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16350714.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Bone Density Conservation Agents; 0 / Calcium, Dietary; 0 / Hydroxycholecalciferols; 76W6J0943E / Flutamide; SY7Q814VUP / Calcium; URQ2517572 / alfacalcidol
  •  go-up   go-down


24. Weissglas M, Löwik C, Schamhart D, Theuns H, Kurth KH, Papapoulos S: Bone resorption and renal calcium reabsorption in renal cell carcinoma-bearing mice: the effects of bisphosphonate. BJU Int; 2007 Jun;99(6):1530-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone resorption and renal calcium reabsorption in renal cell carcinoma-bearing mice: the effects of bisphosphonate.
  • OBJECTIVE: To examine the contribution of the skeleton and the kidney to the development of humoral hypercalcaemia of malignancy (HHM) in a mouse model of HHM treated with a potent bisphosphonate.
  • Treatment was initiated at a tumour volume (TV) of approximately 100 mm(3) and 500 mm(3), and the mice were monitored for approximately 4 weeks.
  • Serum calcium and phosphate concentrations and trabecular bone volume (TBV) were assessed during and/or after treatment.
  • RESULTS: Athymic mice implanted with the RCC RC-9, developed severe hypercalcaemia and bone resorption.
  • Olpadronate initiated at a Tv of 100 mm(3) prevented the loss of bone induced by RCC RC-9 cells, with a TBV of 12.8 (2.1)%, but the development of hypercalcaemia was unaffected.
  • Olpadronate treatment at a TV of 500 mm(3) did not influence the development of hypercalcaemia and did not protect against bone resorption.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone Resorption / metabolism. Carcinoma, Renal Cell / complications. Diphosphonates / therapeutic use. Hypercalcemia / drug therapy. Kidney Neoplasms / complications

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17428243.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 874HHB2V3S / olpadronic acid; SY7Q814VUP / Calcium
  •  go-up   go-down


25. Moore AF, Wexler TL, Yung RL, Kish J, Larvie M, Lauter K, Arnold A, Finkelstein JS, Burnett-Bowie SM: An unusual case of primary hyperparathyroidism with profoundly elevated parathyroid hormone levels. Endocr Pract; 2008 Oct;14(7):892-7
Genetic Alliance. consumer health - Hyperparathyroidism, primary.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A 28-year-old man with a history of childhood abdominal neuroblastoma treated with chemotherapy and field radiation therapy presented with a 2-week history of persistent left scapular pain and swelling.
  • Single-photon emission computed tomography after intravenous administration of technetium Tc 99m-labeled sestamibi revealed an intense focus of abnormal radiotracer uptake on early and delayed images in the right anterior inferior neck.
  • Computed tomography imaging of the chest and neck revealed a 1.9-cm, smooth, calcified nodule posterior to the right lobe of the thyroid gland and diffusely osteopenic bones with trabecular resorption and numerous scattered lucent regions consistent with brown tumors.
  • CONCLUSIONS: This case highlights the overlap between the clinical findings seen in primary hyperparathyroidism and parathyroid carcinoma.
  • Enhanced understanding of the genetic and molecular bases of primary hyperparathyroidism and parathyroid carcinoma should aid in the diagnosis of these diseases and the care of affected patients.
  • [MeSH-major] Hyperparathyroidism, Primary / diagnosis. Hyperparathyroidism, Primary / metabolism. Parathyroid Hormone / metabolism
  • [MeSH-minor] Adult. Humans. Male. Parathyroid Neoplasms / metabolism. Parathyroid Neoplasms / pathology. Technetium Tc 99m Sestamibi. Tomography, Emission-Computed, Single-Photon. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18996820.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDC73 protein, human; 0 / Parathyroid Hormone; 0 / Tumor Suppressor Proteins; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


26. Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T: Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. Cancer Sci; 2009 Jan;100(1):189-94
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to examine in vivo the antitumor activities of miriplatin suspended in an oily lymphographic agent (Lipiodol Ultra-Fluide, LPD) against human hepatocellular carcinoma (HCC) after the intra-hepatic arterial administration, we have developed a novel orthotopic model of HCC in which the human hepatoma cell line Li-7 was successively implanted and maintained in the liver of nude rats.
  • Li-7 tumors established in nude rat livers displayed a trabecular structure similar to their original morphology, and were exclusively supplied by the hepatic artery, suggesting that they exhibited in part the conditions of human HCC.
  • In addition, at the therapeutic dose, miriplatin/LPD as well as cisplatin suspended in LPD (400 microg/head) was shown to be more active than zinostatin stimalamer suspended in LPD (20 microg/head) against Li-7 tumors after a single intra-hepatic arterial administration.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Iodized Oil / administration & dosage. Liver Neoplasms, Experimental / drug therapy. Organoplatinum Compounds / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037997.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Adducts; 0 / Organoplatinum Compounds; 780F0P8N4I / miriplatin; 8001-40-9 / Iodized Oil; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Kurth AA, Kim SZ, Shea M, Bauss F, Hayes WC, Müller R: Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis. J Bone Miner Metab; 2007;25(2):86-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis.
  • Walker carcinosarcoma cells were implanted into the left femur of female rats that received 26-day ibandronate pretreatment followed by continued therapy or ibandronate posttreatment only.
  • At endpoint, excised femurs were scanned using microcomputed tomography (microCT) to assess bone volume density, bone mineral content, trabecular number/thickness, and separation for cortical plus trabecular bone or trabecular bone alone.
  • Compared with the nonimplanted right femur, bone volume and surface density and trabecular number and thickness were reduced in the distal left femur following tumor cell implantation. microCT analysis revealed greater cortical and trabecular bone mineral content in the preventative and interventional (pre-post tumor) ibandronate group, and the interventional (post-tumor) ibandronate group, versus the tumor-only group.
  • After preventative and interventional ibandronate, bone volume density and trabecular thickness were 13% and 60% greater, respectively, than in the post-tumor treatment group.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone and Bones / pathology. Carcinoma 256, Walker / pathology. Diphosphonates / therapeutic use
  • [MeSH-minor] Animals. Disease Models, Animal. Female. Femur / drug effects. Femur / pathology. Image Processing, Computer-Assisted. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1997 May 15;99(10 ):2509-17 [9153295.001]
  • [Cites] J Bone Miner Res. 2002 Jul;17 (7):1139-47 [12096826.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5452-7 [8221685.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 May;20(5):685-93 [6428894.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3890-4 [9307266.001]
  • [Cites] Phys Med Biol. 1994 Jan;39(1):145-64 [7651993.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3219-24 [12149294.001]
  • [Cites] Br J Haematol. 1997 Sep;98(3):665-72 [9332325.001]
  • [Cites] Endocrinology. 1996 Jun;137(6):2324-33 [8641182.001]
  • [Cites] N Engl J Med. 1998 Aug 6;339(6):357-63 [9691101.001]
  • [Cites] J Bone Miner Res. 1994 Feb;9(2):221-30 [8140935.001]
  • [Cites] J Bone Miner Res. 2001 Nov;16(11):2027-34 [11697798.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):698-705 [8698861.001]
  • [Cites] Anat Rec. 1997 Dec;249(4):458-68 [9415453.001]
  • [Cites] Osteoporos Int. 2001;12 (11):936-41 [11804020.001]
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):126-30 [10697328.001]
  • [Cites] Bone. 2004 Apr;34(4):736-46 [15050906.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):3080-8 [10898355.001]
  • [Cites] Osteoporos Int. 2004 Jun;15(6):423-33 [15205712.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4418-24 [11389070.001]
  • [Cites] Bone. 2002 Jan;30(1):300-6 [11792601.001]
  • [Cites] J Bone Miner Res. 2003 Nov;18(11):1932-41 [14606504.001]
  • [Cites] J Bone Miner Res. 1995 Oct;10(10):1478-87 [8686503.001]
  • [Cites] Osteoporos Int. 1998;8(2):97-103 [9666930.001]
  • [Cites] Calcif Tissue Int. 1996 Jan;58(1):24-9 [8825235.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):91-8 [8508433.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:453-65 [10415748.001]
  • [Cites] Mol Pharmacol. 1996 Nov;50(5):1127-38 [8913344.001]
  • [Cites] J Bone Miner Res. 1996 Oct;11(10 ):1482-91 [8889848.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):468-77 [14506749.001]
  • [Cites] Osteoporos Int. 2002 Oct;13(10):816-23 [12378371.001]
  • [Cites] J Bone Miner Res. 1999 Jul;14(7):1167-74 [10404017.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3551-7 [7627963.001]
  • [Cites] Cancer Res. 1984 Jul;44(7):3007-11 [6233002.001]
  • [Cites] J Cancer Res Clin Oncol. 1987;113(6):539-43 [3119600.001]
  • [Cites] J Orthop Res. 2001 Mar;19(2):200-5 [11347691.001]
  • [Cites] J Cancer Res Clin Oncol. 1986;111(1):35-41 [3949849.001]
  • [Cites] Drugs. 2000 Mar;59(3):391-9 [10776826.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):94-8 [11310206.001]
  • [Cites] Oncology. 1988;45(1):41-6 [3340393.001]
  • [Cites] J Bone Miner Res. 2004 Nov;19(11):1787-96 [15476578.001]
  • (PMID = 17323177.001).
  • [ISSN] 0914-8779
  • [Journal-full-title] Journal of bone and mineral metabolism
  • [ISO-abbreviation] J. Bone Miner. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; UMD7G2653W / ibandronic acid
  •  go-up   go-down


28. Bacchi CE, Silva TR, Zambrano E, Plaza J, Suster S, Luzar B, Lamovec J, Pizzolitto S, Falconieri G: Epithelioid angiosarcoma of the skin: a study of 18 cases with emphasis on its clinicopathologic spectrum and unusual morphologic features. Am J Surg Pathol; 2010 Sep;34(9):1334-43
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid angiosarcoma of the skin: a study of 18 cases with emphasis on its clinicopathologic spectrum and unusual morphologic features.
  • Diverging phenotypes included syncytial growth of large cells with clear nuclei and prominent nucleoli, micronodules of tumor cells scattered in dermis, predominance of discohesive plasmacytoid polygonal cells with abundant bright eosinophilic cytoplasm, sheets of clear cells with coarse granular cytoplasm, trabecular and cord arrangement of tumor cells splaying the dermal collagen, or a pseudoglandular appearance owing to clear cell tubular arrangement with open lumina.
  • These cases posed further diagnostic challenges simulating lymphoma, melanoma, lymphoepithelioma-like carcinoma, adnexal carcinoma, and neuroendocrine carcinoma.
  • Therapeutic modalities included combined local excision, chemotherapy, and radiotherapy, depending on patient clinical status.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697249.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


29. Jianmin Z, Hongfang W, Meifu F: Resistance of multicellular aggregates to pharmorubicin observed in human hepatocarcinoma cells. Braz J Med Biol Res; 2002 Feb;35(2):255-60
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The culture products exhibited structural characteristics somewhat similar to those of trabecular hepatocarcinoma in vivo.
  • This three-dimensional culture model may be used to investigate the mechanisms of multicellular drug resistance of hepatocarcinoma and to screen new anticancer drugs.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11847530.001).
  • [ISSN] 0100-879X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


30. Shimoyama S, Nozaki K, Kaminishi M, Motoi N, Murakami T: A rare case of alpha-fetoprotein-producing early gastric cancer. Hepatogastroenterology; 2001 May-Jun;48(39):687-91
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of the alpha-fetoprotein-producing gastric cancer is advanced at the time of presentation, and alpha-fetoprotein-producing early gastric cancer is extremely rare.
  • A 71-year-old-male patient underwent total gastrectomy due to a depressed type of gastric cancer in the upper third of the stomach.
  • Histological examination revealed that the tumor invasion was limited to the submucosal layer, and that the tumor consisted of both well-differentiated, papillo-tubular growth areas and trabecular and medullary growth areas resembling hepatoid carcinoma.
  • The predominance of a strong-bound fraction with lectin, which was demonstrated by lens culinalis agglutinin affinity chromatography, suggests that the alpha-fetoprotein carbohydrate chain species in the present case was a hepatic type.
  • The patient received adjuvant intravenous chemotherapy consisting of 5-fluorouracil and cisplatin, and has been further supported by oral 5-fluorouracil administration.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Chemotherapy, Adjuvant. Combined Modality Therapy. Gastrectomy. Gastric Mucosa / pathology. Humans. Male. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11462904.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


31. Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, Baker JF, Chaikin MA, Donatelli RR, Franks CF, Zeng L, Crysler C, Chen Y, Yurkow EJ, Boczon L, Meegalla SK, Wilson KJ, Wall MJ, Chen J, Ballentine SK, Ott H, Baumann C, Lawrence D, Tomczuk BE, Molloy CJ: JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther; 2009 Nov;8(11):3151-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • H460 lung adenocarcinoma cells did not express CSF-1R and were not growth inhibited by JNJ-28312141 in vitro.
  • Furthermore, the tumor microvasculature was reduced in JNJ-28312141-treated mice, consistent with a role for macrophages in tumor angiogenesis.
  • In separate studies, JNJ-28312141 was compared with zoledronate in a model in which MRMT-1 mammary carcinoma cells inoculated into the tibias of rats led to severe cortical and trabecular bone lesions.
  • To more fully define the therapeutic potential of this new agent, JNJ-28312141 was evaluated in a FLT3-dependent acute myeloid leukemia tumor xenograft model and caused tumor regression.
  • In summary, this novel CSF-1R/FLT3 inhibitor represents a new agent with potential therapeutic activity in acute myeloid leukemia and in settings where CSF-1-dependent macrophages and osteoclasts contribute to tumor growth and skeletal events.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Imidazoles / pharmacology. Leukemia, Myeloid, Acute / drug therapy. Piperidines / pharmacology. Protein Kinase Inhibitors / pharmacology. Receptor, Macrophage Colony-Stimulating Factor / antagonists & inhibitors. fms-Like Tyrosine Kinase 3 / antagonists & inhibitors
  • [MeSH-minor] Animals. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Non-Small-Cell Lung / pathology. Cell Growth Processes / drug effects. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Lung Neoplasms / drug therapy. Lung Neoplasms / enzymology. Lung Neoplasms / pathology. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / enzymology. Mammary Neoplasms, Experimental / pathology. Mice. Mice, Nude. Osteoclasts / drug effects. Osteoclasts / pathology. Rats. Rats, Sprague-Dawley. Substrate Specificity. Xenograft Model Antitumor Assays


32. Mundy GR, Yoneda T, Hiraga T: Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol; 2001 Apr;28(2 Suppl 6):35-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast cancer cells and other tumor types influence osteoclastic bone resorption by increasing the number of osteoclasts and enhancing their resorptive activity.
  • A single 3 microg intravenous injection of zoledronic acid (Zometa; Novartis Pharmaceuticals Corp, East Hanover, NJ), a new highly potent bisphosphonate, prevented destruction of trabecular bone in an orthotopic mouse mammary tumor model.
  • Tumor volume in bone was decreased by zoledronic acid in a dose-dependent manner in the same model, and tumor cell apoptosis was increased by zoledronic acid in bone metastases in the 4T1 murine model of mammary carcinoma metastasis.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Bone and Bones / drug effects. Diphosphonates / pharmacology. Imidazoles / pharmacology
  • [MeSH-minor] Animals. Drug Evaluation, Preclinical. Mammary Neoplasms, Experimental. Mice. Models, Animal. Neoplasm Metastasis / pathology. Rats

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11346863.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  • [Number-of-references] 75
  •  go-up   go-down


33. Rauch DA, Hurchla MA, Harding JC, Deng H, Shea LK, Eagleton MC, Niewiesk S, Lairmore MD, Piwnica-Worms D, Rosol TJ, Weber JD, Ratner L, Weilbaecher KN: The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice. PLoS One; 2010 Dec 30;5(12):e15755
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arf(-/-) mice displayed increased osteoblast (OB) and osteoclast (OC) activity with a significant net increase in trabecular bone volume.
  • Mice transgenic for the Tax oncogene develop lymphocytic tumors with associated osteolytic lesions, while Tax+Arf(-/-) mice uniformly developed spontaneous OS by 7 months of age.
  • Hypothesizing that inhibition of ARF-regulated bone remodeling would repress development of OS, we demonstrated that treatment of Tax+Arf(-/-) mice with zoledronic acid, a bisphosphonate inhibitor of OC activity and repressor of bone turnover, prevented or delayed the onset of OS.
  • Finally, these data underscore the potential of targeting bone remodeling as adjuvant therapy or in patients with genetic predispositions to prevent the development of OS.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] DNA Cell Biol. 2007 Jan;26(1):1-18 [17263592.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6222s-6230s [17062705.001]
  • [Cites] J Bone Miner Metab. 2007;25(2):93-8 [17323178.001]
  • [Cites] Curr Med Chem. 2007;14(17):1815-27 [17627519.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7308-18 [17671200.001]
  • [Cites] J Cell Biochem. 2007 Dec 15;102(6):1333-42 [17907152.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19861-6 [18077419.001]
  • [Cites] Int J Oncol. 2008 Jan;32(1):17-31 [18097539.001]
  • [Cites] Mol Cell Biol. 2008 Feb;28(3):1068-80 [18070929.001]
  • [Cites] Annu Rev Pathol. 2008;3:457-84 [18039135.001]
  • [Cites] Bone. 2008 Jun;42(6):1007-13 [18406675.001]
  • [Cites] Cancer Treat Rev. 2008;34 Suppl 1:S25-30 [18486347.001]
  • [Cites] Genes Dev. 2008 Jun 15;22(12):1662-76 [18559481.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11851-6 [18697945.001]
  • [Cites] Mol Cancer Ther. 2008 Nov;7(11):3461-9 [19001431.001]
  • [Cites] J Biol Chem. 2009 Feb 13;284(7):4658-66 [19059914.001]
  • [Cites] Blood. 2009 Feb 12;113(7):1493-500 [18971418.001]
  • [Cites] Nat Med. 2009 Apr;15(4):455-61 [19305414.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Apr;9(4):511-23 [19374604.001]
  • [Cites] Bone. 2009 May;44(5):908-16 [19442620.001]
  • [Cites] J Cell Physiol. 2009 Oct;221(1):204-12 [19496172.001]
  • [Cites] J Bone Joint Surg Br. 2009 Sep;91(9):1223-6 [19721051.001]
  • [Cites] Oncogene. 2009 Sep 10;28(36):3209-20 [19561638.001]
  • [Cites] Curr Cancer Drug Targets. 2009 Nov;9(7):807-23 [20025569.001]
  • [Cites] Retrovirology. 2009;6:116 [20017942.001]
  • [Cites] Clin Cancer Res. 2010 Apr 15;16(8):2363-74 [20371692.001]
  • [Cites] Lancet Oncol. 2010 May;11(5):421-8 [20362507.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2658-69 [10541552.001]
  • [Cites] Nat Cell Biol. 1999 May;1(1):20-6 [10559859.001]
  • [Cites] Genes Dev. 2000 Sep 15;14(18):2358-65 [10995391.001]
  • [Cites] J Virol. 2001 Mar;75(5):2185-93 [11160722.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4621-8 [11498785.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3848-53 [11891301.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2184-91 [11929842.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):584-93 [12154351.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Nov;259(10):540-2 [12434189.001]
  • [Cites] J Rheumatol. 2003 Aug;30(8):1799-810 [12913938.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(18):6216-20 [2994066.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3042-8 [8187094.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 [7862633.001]
  • [Cites] Cell. 1997 Nov 28;91(5):649-59 [9393858.001]
  • [Cites] Endocr Rev. 1998 Feb;19(1):18-54 [9494779.001]
  • [Cites] J Bone Miner Res. 1998 Apr;13(4):581-9 [9556058.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2424-33 [9694806.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Feb 16;255(2):491-4 [10049736.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2217-22 [10232611.001]
  • [Cites] Calcif Tissue Int. 1999 Jul;65(1):53-8 [10369734.001]
  • [Cites] J Biol Chem. 2004 Dec 17;279(51):53317-22 [15485814.001]
  • [Cites] J Bone Miner Res. 2005 Jan;20(1):58-66 [15619670.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2406-11 [15781656.001]
  • [Cites] N Engl J Med. 2005 Sep 1;353(9):898-908 [16135834.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2452-61 [15972450.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1713-20 [16121404.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4294-302 [16118323.001]
  • [Cites] Mol Cell. 2005 Dec 9;20(5):699-708 [16337594.001]
  • [Cites] J Cell Biol. 2006 Jan 2;172(1):115-25 [16380437.001]
  • [Cites] Clin Orthop Relat Res. 2006 Jan;442:216-22 [16394764.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):929-35 [16424027.001]
  • [Cites] Prostate. 2006 Aug 1;66(11):1213-22 [16683269.001]
  • [Cites] Ann Biomed Eng. 2006 Jul;34(7):1149-56 [16786394.001]
  • [Cites] Ann N Y Acad Sci. 2006 Dec;1092:385-96 [17308163.001]
  • (PMID = 21209895.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA094056; United States / NCI NIH HHS / CA / T32 CA113275; United States / NCI NIH HHS / CA / R01 CA120436; United States / NCI NIH HHS / CA / CA63417; United States / NCI NIH HHS / CA / CA10521; United States / NCI NIH HHS / CA / P50 CA94056; United States / NCI NIH HHS / CA / R01 CA063417; United States / NIAMS NIH HHS / AR / P30 AR057235; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Gene Products, tax; 0 / Imidazoles; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; 6XC1PAD3KF / zoledronic acid
  • [Other-IDs] NLM/ PMC3012707
  •  go-up   go-down






Advertisement